Financial Report: Abbott 3Q08

Abbott

3Q Revenues: $7.5 billion (+18%)

3Q Earnings: $1.1 billion (+51%)

YTD Revenues: $22.0 billion (+15%)

YTD Earnings: $3.3 billion (+39%)

Comments: Worldwide pharmaceutical sales were $4.1 billion in the quarter (+17%), driven by growth in Humira, Kaletra, TriCor, and Niaspan. U.S. sales were $3.7 billion (+18%). International sales were $2.0 billion (+22%) with a positive impact of exchange of 10%. Humira sales reached $1.2 billion in the quarter (+50%). Kaletra sales were $387 million (+14%). TriCor sales were up 11% to $334 million. Niaspan sales were up 16% to $194 million. Depakote sales were down 17% to $317 million due to generic competition. Worldwide vascular sales were $636 million in the quarter (+58%). Coronary stents accounted for $383 million (+135%).